Axsome Therapeutics
Price & Volume
Stats
See more52W Range | $64.11-$139.12 |
Market Cap | $6.1B |
Shares Short | 5M |
Financials
See moreRevenue (12 Mos) | $385.6M |
Revenue Growth (YoY) | 66% |
Gross Profit (12 Mos) | $352.3M |
Diluted EPS | -$5.99 |
News
See moreYahoo Finance • 13 days ago
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
Yahoo Finance • 29 days ago
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
Yahoo Finance • 30 days ago
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
Yahoo Finance • 4 months ago
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
About
CEO | Dr. Herriot Tabuteau M.D. |
Address | One World Trade Center, New York, NY, United States, 10007 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 683 |
